Kisspeptin-10

Kisspeptin-10 (Kp-10) is a bioactive 10-amino acid peptide derived from the KISS1 gene, corresponding to amino acids 45-54 of metastin. It acts as a critical regulator of reproductive function through activation of the GPR54 receptor, stimulating the release of gonadotropin-releasing hormone (GnRH) and subsequently luteinizing hormone (LH) and follicle-stimulating hormone (FSH). Originally discovered for its anti-metastatic properties in cancer, kisspeptin-10 has emerged as a key player in the hypothalamic-pituitary-gonadal axis. The peptide shows therapeutic potential for fertility disorders including PCOS, hypothalamic amenorrhea, and male hypogonadism. It is currently experimental with no FDA approval and is classified as a substantial safety risk for compounding pharmacy use.

Key Benefits

Kisspeptin-10 is a potent regulator of reproductive hormone release, with particularly robust effects in men where it stimulates luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion at doses as low as 0.3 nmol/kg^[1][2]. In clinical trials, continuous infusion increases testosterone levels, LH pulse frequency, and pulse size in healthy men^[1]. The peptide shows significant therapeutic potential for female reproductive disorders, with kisspeptin receptor agonists demonstrating efficacy in treating polycystic ovary syndrome and hypothalamic amenorrhea^[4]. Beyond reproductive function, Kisspeptin-10 exhibits potent anti-tumor and anti-angiogenic properties, significantly inhibiting tumor growth in xenografted mice through suppression of VEGF expression and FAK/Rho GTPase signaling pathways^[3]. The peptide increases collagen content in cardiac tissue through focal adhesion kinase activity, suggesting potential cardiovascular remodeling effects^[5]. Kisspeptin-10 also participates in metabolic regulation, enhancing glucose-stimulated insulin secretion from pancreatic beta cells and modulating hepatic glucose production, indicating broader metabolic functions beyond its primary reproductive role^[9].

Safety Profile

Kisspeptin-10 currently lacks FDA approval for any medical use, and the FDA has classified it as presenting substantial safety risks for compounding pharmacies due to insufficient long-term safety data and concerns about immunogenicity when administered via subcutaneous or intramuscular injection^[10]. Clinical trials in humans have demonstrated the peptide to be generally well-tolerated during short-term administration with monitoring of heart rate and blood pressure, though no serious adverse events were detailed in published studies^[2]. Common side effects are typically mild and transient, including nausea, headache, injection site reactions, and postural dizziness^[10]. However, significant cardiovascular safety concerns have emerged from preclinical research showing that Kisspeptin-10 functions as a potent vasoconstrictor and accelerates atherosclerotic plaque development and instability in animal models, with these pro-atherogenic effects mediated through increased monocyte adhesion, vascular inflammation, and enhanced inflammatory markers including TNF-α and IL-6^[7][8]. The peptide's vasoconstrictor properties, while substantially less potent than endothelin-1, can reduce peripheral blood flow through microvascular constriction^[8]. Sexual dimorphism in response is notable, with women showing hormone responses only during the preovulatory phase of the menstrual cycle, while men respond consistently at all phases^[2]. Twice-daily administration in women with hypothalamic amenorrhea results in tachyphylaxis due to excessive receptor desensitization^[10]. The peptide is contraindicated in pregnant and breastfeeding women due to unknown developmental effects, and individuals with cardiovascular conditions should exercise particular caution given its atherosclerotic and vasoconstrictor properties^[7][8][10].